---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000057"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-09-28T13:32:06+00:00"
generated_at: "2026-10-12T13:33:05.729794+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oncolytics: REO 033 CRC study sites nearly all activated; interim Part A data due year-end 2026

## Summary
- Part A of randomized REO 033 to enroll ~60 patients with second-line RAS-mutant MSS metastatic colorectal cancer; ORR is primary endpoint, with PFS, OS, safety and biomarkers.
- Interim Part A data expected by year-end 2026, based on number of evaluable patients enrolled by end of October; multiple patients now on study.
- REO 022 prior data: ORR 33% vs ~6-11% historical benchmark; median PFS 16.6 months vs ~5.7; median OS 27.0 months vs ~11.2; median duration of response 19.5 months.
- FDA alignment on pivotal Part B expansion: potential accelerated approval on objective response rate; progression-free survival basis for full approval; Part A data to inform Part B.
- RO 033 tests pelareorep plus FOLFIRI and bevacizumab versus FOLFIRI and bevacizumab; COO John McAdory cites strong enrollment momentum.

## SEC filing metadata
- accession: 0001129928-26-000057
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-09-28T13:32:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000057/0001129928-26-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000057/oncy-20260928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000057
- JSON: https://secwatch.observer/filing/0001129928-26-000057.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.